Palonossetrom Kalceks (Palonosetron)

Palonosetron, the active ingredient in Palonossetrom Kalceks, is a selective 5-HT3 receptor antagonist presented as a 0.075 mg/2 ml solution for intravenous use. It is used to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients.

GNH USA supplies Palonossetrom Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron is employed in the management of nausea and vomiting associated with cancer therapy, acting on the serotonergic pathway. - Chemotherapy‑induced nausea and vomiting (CINV): Provides long‑lasting prevention of acute and delayed episodes. - Post‑operative nausea and vomiting (PONV): Reduces incidence of nausea after surgical procedures. - Radiotherapy‑induced nausea and vomiting: Helps control ​the ​vomiting reflex ​triggered ​by ​radiation ​treatment.

Adverse reactions to palonosetron are generally mild to moderate and vary with the route of administration.

Common Side Effects: - Headache - Constipation - Fatigue - Diarrhoea - Dizziness - Injection site pain

Serious or Rare Side Effects: - Severe hypersensitivity (anaphylaxis, angio‑angulation ​       ​    ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​) - QT‑interval prolongation - Serotonin syndrome - Cardiac arrhythmias - Severe constipation leading ​to ​bowel ​obstruction

Palonosetron should be used with caution in patients with known ​  ​  ​  ​  ​  ​  … -   g  ?   t  \